title: The antimicrobial activities of phenylbutyrates against Helicobacter pylori.
abstract: Three phenyl derivatives of butyrate, 2-phenylbutyrate (2-PB), 3-phenylbutyrate (3-PB) and 4-phenylbutyrate (4-PB), were evaluated in terms of their antibacterial and cytotoxic activities. Our results indicated that PBs demonstrated specific inhibitory activity against Helicobacter pylori and Escherichia coli but did not influence the growth of Bifidobacterium bifidium and Lactobacillus reuteri. PBs also exhibited synergistic effects on H. pylori ATCC 43504 especially at pH 5.5. In the protein expression profiles in H. pylori treated by phenylbutyrates, we also found that three protein spots identified as oxidative stress-related proteins were significantly up-regulated, confirming the response of H. pylori when exposed to PBs. Due to their antibacterial activities and low or slight cytotoxicities, PBs are potential candidates for the treatment of H. pylori infection. This is the first study to discover the antibiotic effects of 2-PB, 3-PB and 4-PB (Buphenyl).
authors.affiliation: Graduate Institute of Bioresource, National Pingtung University of Science and Technology, Pingtung, Taiwan, ROC.
authors.forename: Chung-Yi
authors.initials: CY
authors.lastname: Lo
authors.forename: Hsueh-Ling
authors.initials: HL
authors.lastname: Cheng
authors.forename: Jue-Liang
authors.initials: JL
authors.lastname: Hsu
authors.forename: Ming-Hui
authors.initials: MH
authors.lastname: Liao
authors.forename: Rong-Lang
authors.initials: RL
authors.lastname: Yen
authors.forename: Yo-Chia
authors.initials: YC
authors.lastname: Chen
mesh_terms: D000818:Animals; D000890:Anti-Infective Agents / Q000737:chemistry / Q000494:pharmacology* / Q000633:toxicity; D001426:Bacterial Proteins / Q000378:metabolism; D001644:Bifidobacterium / Q000187:drug effects / Q000254:growth & development; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D006224:Cricetinae; D004357:Drug Synergism; D004926:Escherichia coli / Q000187:drug effects; D016480:Helicobacter pylori / Q000187:drug effects* / Q000378:metabolism; D006863:Hydrogen-Ion Concentration; D052200:Limosilactobacillus reuteri / Q000187:drug effects / Q000254:growth & development; D008795:Metronidazole / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D010654:Phenylbutyrates / Q000737:chemistry / Q000494:pharmacology* / Q000633:toxicity; D015854:Up-Regulation
chemical_list: D000890:Anti-Infective Agents; D001426:Bacterial Proteins; D010654:Phenylbutyrates; D008795:Metronidazole